{"id":41370,"date":"2024-02-14T09:10:35","date_gmt":"2024-02-14T15:10:35","guid":{"rendered":"https:\/\/leukemiarf.org\/?p=41370"},"modified":"2024-05-02T10:03:30","modified_gmt":"2024-05-02T15:03:30","slug":"blinatumomab-b-cell-acute-lymphoblastic-leukemia","status":"publish","type":"post","link":"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/","title":{"rendered":"Blina may be effective in first-line treatment of Pediatric B-ALL"},"content":{"rendered":"\n

Blinatumomab, or Blina, appears to be a safe and effective first-line treatment option for young patients with B-cell acute lymphoblastic leukemia (B-ALL) who don\u2019t tolerate chemotherapy, according to a study recently published in the Journal of Clinical Oncology<\/a><\/strong><\/em>.<\/p>\n\n\n\n

Chemotherapy treatments can have a negative impact on a child\u2019s quality of life. This study looked at the possibility that Blina could be a less toxic first step in treatment for some patients.<\/p>\n\n\n\n

From February 2018 to February 2023, 105 patients were followed.<\/p>\n\n\n\n

After analysis, researchers concluded that Blina is safe and effective in first-line treatment of chemotherapy-intolerant children and young persons with ALL.<\/p>\n\n\n\n

Read full article here<\/a><\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"

Blinatumomab, or Blina, appears to be a safe and effective first-line treatment option for young patients with B-cell acute lymphoblastic leukemia (B-ALL) who don\u2019t tolerate chemotherapy, according to a study…<\/p>\n","protected":false},"author":17,"featured_media":40690,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":[],"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueState":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_VenueShowMap":false,"_VenueShowMapLink":false,"footnotes":""},"categories":[50,72,1],"tags":[76],"yoast_head":"\nBlina may be effective in first-line treatment of Pediatric B-ALL — Leukemia Research Foundation<\/title>\n<meta name=\"description\" content=\"Blinatumomab, or Blina, appears to be a safe and effective first-line treatment option for young patients with B-cell acute lymphoblastic leukemia (B-ALL)\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Blina may be effective in first-line treatment of Pediatric B-ALL\" \/>\n<meta property=\"og:description\" content=\"Blinatumomab, or Blina, appears to be a safe and effective first-line treatment option for young patients with B-cell acute lymphoblastic leukemia (B-ALL)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/\" \/>\n<meta property=\"og:site_name\" content=\"Leukemia Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LeukemiaResearch\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-14T15:10:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-02T15:03:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/leukemiarf.org\/wp-content\/uploads\/2023\/09\/AML-immunotherapy-treatment-368x245-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"368\" \/>\n\t<meta property=\"og:image:height\" content=\"245\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Maureen Jones\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Maureen Jones\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/\"},\"author\":{\"name\":\"Maureen Jones\",\"@id\":\"https:\/\/leukemiarf.org\/#\/schema\/person\/5eb000b67df01a5b170a920d3037a1af\"},\"headline\":\"Blina may be effective in first-line treatment of Pediatric B-ALL\",\"datePublished\":\"2024-02-14T15:10:35+00:00\",\"dateModified\":\"2024-05-02T15:03:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/\"},\"wordCount\":115,\"publisher\":{\"@id\":\"https:\/\/leukemiarf.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/leukemiarf.org\/wp-content\/uploads\/2023\/09\/AML-immunotherapy-treatment-368x245-1.png\",\"keywords\":[\"Acute Lymphocytic Leukemia\"],\"articleSection\":[\"News\",\"Research breakthroughs\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/\",\"url\":\"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/\",\"name\":\"Blina may be effective in first-line treatment of Pediatric B-ALL — Leukemia Research Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/leukemiarf.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/leukemiarf.org\/wp-content\/uploads\/2023\/09\/AML-immunotherapy-treatment-368x245-1.png\",\"datePublished\":\"2024-02-14T15:10:35+00:00\",\"dateModified\":\"2024-05-02T15:03:30+00:00\",\"description\":\"Blinatumomab, or Blina, appears to be a safe and effective first-line treatment option for young patients with B-cell acute lymphoblastic leukemia (B-ALL)\",\"breadcrumb\":{\"@id\":\"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/#primaryimage\",\"url\":\"https:\/\/leukemiarf.org\/wp-content\/uploads\/2023\/09\/AML-immunotherapy-treatment-368x245-1.png\",\"contentUrl\":\"https:\/\/leukemiarf.org\/wp-content\/uploads\/2023\/09\/AML-immunotherapy-treatment-368x245-1.png\",\"width\":368,\"height\":245},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/leukemiarf.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Blina may be effective in first-line treatment of Pediatric B-ALL\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/leukemiarf.org\/#website\",\"url\":\"https:\/\/leukemiarf.org\/\",\"name\":\"Leukemia Research Foundation\",\"description\":\"A world without leukemia\",\"publisher\":{\"@id\":\"https:\/\/leukemiarf.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/leukemiarf.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/leukemiarf.org\/#organization\",\"name\":\"Leukemia Research Foundation\",\"alternateName\":\"LRF\",\"url\":\"https:\/\/leukemiarf.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/leukemiarf.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/leukemiarf.org\/wp-content\/uploads\/2022\/03\/Icon_Red.png\",\"contentUrl\":\"https:\/\/leukemiarf.org\/wp-content\/uploads\/2022\/03\/Icon_Red.png\",\"width\":118,\"height\":118,\"caption\":\"Leukemia Research Foundation\"},\"image\":{\"@id\":\"https:\/\/leukemiarf.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/LeukemiaResearch\",\"https:\/\/www.youtube.com\/channel\/UC923DiAUlYsTrnOtm1-rbYg\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/leukemiarf.org\/#\/schema\/person\/5eb000b67df01a5b170a920d3037a1af\",\"name\":\"Maureen Jones\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/leukemiarf.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/64f0fd6b96b07ebeb7e4ffa17e7e7890?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/64f0fd6b96b07ebeb7e4ffa17e7e7890?s=96&d=mm&r=g\",\"caption\":\"Maureen Jones\"},\"sameAs\":[\"https:\/\/leukemiarf.org\/\"],\"url\":\"https:\/\/leukemiarf.org\/news\/author\/maureenleukemiarf-org\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Blina may be effective in first-line treatment of Pediatric B-ALL — Leukemia Research Foundation","description":"Blinatumomab, or Blina, appears to be a safe and effective first-line treatment option for young patients with B-cell acute lymphoblastic leukemia (B-ALL)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/","og_locale":"en_US","og_type":"article","og_title":"Blina may be effective in first-line treatment of Pediatric B-ALL","og_description":"Blinatumomab, or Blina, appears to be a safe and effective first-line treatment option for young patients with B-cell acute lymphoblastic leukemia (B-ALL)","og_url":"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/","og_site_name":"Leukemia Research Foundation","article_publisher":"https:\/\/www.facebook.com\/LeukemiaResearch","article_published_time":"2024-02-14T15:10:35+00:00","article_modified_time":"2024-05-02T15:03:30+00:00","og_image":[{"width":368,"height":245,"url":"https:\/\/leukemiarf.org\/wp-content\/uploads\/2023\/09\/AML-immunotherapy-treatment-368x245-1.png","type":"image\/png"}],"author":"Maureen Jones","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Maureen Jones","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/#article","isPartOf":{"@id":"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/"},"author":{"name":"Maureen Jones","@id":"https:\/\/leukemiarf.org\/#\/schema\/person\/5eb000b67df01a5b170a920d3037a1af"},"headline":"Blina may be effective in first-line treatment of Pediatric B-ALL","datePublished":"2024-02-14T15:10:35+00:00","dateModified":"2024-05-02T15:03:30+00:00","mainEntityOfPage":{"@id":"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/"},"wordCount":115,"publisher":{"@id":"https:\/\/leukemiarf.org\/#organization"},"image":{"@id":"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/#primaryimage"},"thumbnailUrl":"https:\/\/leukemiarf.org\/wp-content\/uploads\/2023\/09\/AML-immunotherapy-treatment-368x245-1.png","keywords":["Acute Lymphocytic Leukemia"],"articleSection":["News","Research breakthroughs"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/","url":"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/","name":"Blina may be effective in first-line treatment of Pediatric B-ALL — Leukemia Research Foundation","isPartOf":{"@id":"https:\/\/leukemiarf.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/#primaryimage"},"image":{"@id":"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/#primaryimage"},"thumbnailUrl":"https:\/\/leukemiarf.org\/wp-content\/uploads\/2023\/09\/AML-immunotherapy-treatment-368x245-1.png","datePublished":"2024-02-14T15:10:35+00:00","dateModified":"2024-05-02T15:03:30+00:00","description":"Blinatumomab, or Blina, appears to be a safe and effective first-line treatment option for young patients with B-cell acute lymphoblastic leukemia (B-ALL)","breadcrumb":{"@id":"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/#primaryimage","url":"https:\/\/leukemiarf.org\/wp-content\/uploads\/2023\/09\/AML-immunotherapy-treatment-368x245-1.png","contentUrl":"https:\/\/leukemiarf.org\/wp-content\/uploads\/2023\/09\/AML-immunotherapy-treatment-368x245-1.png","width":368,"height":245},{"@type":"BreadcrumbList","@id":"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/leukemiarf.org\/"},{"@type":"ListItem","position":2,"name":"Blina may be effective in first-line treatment of Pediatric B-ALL"}]},{"@type":"WebSite","@id":"https:\/\/leukemiarf.org\/#website","url":"https:\/\/leukemiarf.org\/","name":"Leukemia Research Foundation","description":"A world without leukemia","publisher":{"@id":"https:\/\/leukemiarf.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/leukemiarf.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/leukemiarf.org\/#organization","name":"Leukemia Research Foundation","alternateName":"LRF","url":"https:\/\/leukemiarf.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/leukemiarf.org\/#\/schema\/logo\/image\/","url":"https:\/\/leukemiarf.org\/wp-content\/uploads\/2022\/03\/Icon_Red.png","contentUrl":"https:\/\/leukemiarf.org\/wp-content\/uploads\/2022\/03\/Icon_Red.png","width":118,"height":118,"caption":"Leukemia Research Foundation"},"image":{"@id":"https:\/\/leukemiarf.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LeukemiaResearch","https:\/\/www.youtube.com\/channel\/UC923DiAUlYsTrnOtm1-rbYg"]},{"@type":"Person","@id":"https:\/\/leukemiarf.org\/#\/schema\/person\/5eb000b67df01a5b170a920d3037a1af","name":"Maureen Jones","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/leukemiarf.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/64f0fd6b96b07ebeb7e4ffa17e7e7890?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/64f0fd6b96b07ebeb7e4ffa17e7e7890?s=96&d=mm&r=g","caption":"Maureen Jones"},"sameAs":["https:\/\/leukemiarf.org\/"],"url":"https:\/\/leukemiarf.org\/news\/author\/maureenleukemiarf-org\/"}]}},"_links":{"self":[{"href":"https:\/\/leukemiarf.org\/wp-json\/wp\/v2\/posts\/41370"}],"collection":[{"href":"https:\/\/leukemiarf.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/leukemiarf.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/leukemiarf.org\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/leukemiarf.org\/wp-json\/wp\/v2\/comments?post=41370"}],"version-history":[{"count":4,"href":"https:\/\/leukemiarf.org\/wp-json\/wp\/v2\/posts\/41370\/revisions"}],"predecessor-version":[{"id":41725,"href":"https:\/\/leukemiarf.org\/wp-json\/wp\/v2\/posts\/41370\/revisions\/41725"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/leukemiarf.org\/wp-json\/wp\/v2\/media\/40690"}],"wp:attachment":[{"href":"https:\/\/leukemiarf.org\/wp-json\/wp\/v2\/media?parent=41370"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/leukemiarf.org\/wp-json\/wp\/v2\/categories?post=41370"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/leukemiarf.org\/wp-json\/wp\/v2\/tags?post=41370"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}